ALX Oncology Holdings Inc (ALXO): Shareholders' Equity
$25.98M
As of 2025-12-31
$136.19M
As of 2026-06-30
-53.8%
3-year compound annual growth
-42.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.98M | -77.1% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $113.62M | -40.1% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $189.71M | -28.0% | 2026-03-09, Balance as of period end |
| 2022-12-31 | $263.46M | -27.4% | 2025-03-06, Balance as of period end |
| 2021-12-31 | $363.05M | -15.5% | 2024-03-07, Balance as of period end |
| 2020-12-31 | $429.85M | n/m | 2023-03-09, Balance as of period end |
| 2019-12-31 | -$70.64M | n/m | 2022-02-28, Balance as of period end |
| 2018-12-31 | -$51.78M | n/a | 2021-03-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $25.98M | -77.1% |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $29.55M | -42.7% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $27.98M | -55.3% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.22M | +273.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $56.11M | +37.8% |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗